Expression level of MDR1 message in peripheral blood leukocytes from healthy adults: A competitive nucleic acid sequence-based amplification assay for its determination

Clinical Chemistry and Laboratory Medicine

Volumn 42, Issue 10, 2004, Pages 1098-1101

  Kobayashi, Hiroyuki ^a,e   Takemura, Yuzuru ^b   Hayashi, Tsukasa ^c   Ujiiye, Takeshi ^c   Kawase, Masako ^c   Niino, Yasuhiro ^a   Miyachi, Hayato ^d   Ohshima, Toshio ^d   Hotta, Tomomitsu ^d  

^a TOKAI UNIVERSITY   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^c KAINOS Laboratories Inc   (Japan)

^d TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Multidrug resistance 1 gene (MDR1); Nucleic acid sequence based amplification; Peripheral blood cells; Reference intervals

Indexed keywords

MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; NUCLEIC ACID;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LEUKOCYTE; MALE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DETERMINATION; QUANTITATIVE ASSAY; REFERENCE VALUE; TUMOR CELL LINE;

ADULT; CASE-CONTROL STUDIES; GENE EXPRESSION; HUMANS; LEUKOCYTES, MONONUCLEAR; P-GLYCOPROTEIN; RNA, MESSENGER; SELF-SUSTAINED SEQUENCE REPLICATION; TUMOR CELLS, CULTURED;

EID: 8344263840     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2004.226     Document Type: Article

References (24)

1. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene 2003;22:7468-85.
2. Kim RB. Drug transporters in HIV therapy. Top HIV Med 2003;11:136-9.
3. Fujimaki S, Funato T, Harigae H, Fujiwara J, Kameoka J, Meguro K, et al. Quantitative analysis of a MDR1 transcript for prediction of drug resistance in acute leukemia. Clin Chem 2002;48:811-7.
4. Debuire B, Sol O, Lemoine A, May E. Nonisotopic competitive RT-PCR assay to measure MDR1 gene expression. Clin Chem 1995;41:819-25.
5. van Hille B, Lohri A, Reuter J, Herrmann R. Nonradioactive quantification of mdr1 mRNA by polymerase chain reaction amplification coupled with HPLC. Clin Chem 1995;41:1087-93.
6. Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 1996; 56:3010-20.
7. Kobayashi H, Takemura Y, Kawai Y, Miyachi H, Kawabata M, Matsumura T, et al. Competitive reverse transcription-polymerase chain reaction assay for quantification of human multidrug resistance 1 (MDR1) gene expression in fresh leukemic cells. J Lab Clin Med 2000;135:199-209.
8. Klimecki WT, Futscher BW, Grogan TM, Dalton WS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994;83:2451-8.
9. Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992; 80:2735-9.
10. Hayashi T, Kobayashi H, Miyachi H, Ohshima T, Ujiiye T, Kawase M, et al. A competitive nucleic acid sequence-based amplification assay for the quantification of human MDR1 transcript in leukemia cells. Clin Chim Acta 2004;342:115-26.
11. Kobayashi H, Takemura Y, Miyachi H, Kawabata M, Mori S, Kawai Y, et al. Quantitative analysis of human multidrug resistance 1 (MDR1) gene expression by nonisotopic competitive reverse transcriptase polymerase chain reaction assay. J Clin Lab Anal 1997;11:258-66.
12. Arkin H, Ohnuma T, Kamen BA, Holland JF, Vallabhajosula S. Multidrug resistance in a human leukemic cell line selected for resistance to trimetrexate. Cancer Res 1989;49:6556-61.
13. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Potentiation of vincristine and adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors. Cancer Res 1983;43:2267-72.
14. Tsuruo T, Iida-Saito H, Kawabata H, Oh-hara T, Hamada H, Utakoji T. Characteristics of resistance to adriamycin in human myelogenous leukemia K562 resistant to adriamycin and in isolated clones. Jpn J Cancer Res 1986;77:682-92.
15. Ralph P, Moore MA, Nilsson K. Lysozyme synthesis by established human and murine histiocytic lymphoma cell lines. J Exp Med 1976;143:1528-33.
16. Yokota J, Akiyama T, Fung YK, Benedict WF, Namba Y, Hanaoka M, et al. Altered expression of the retinoblastoma (RB) gene in small-cell carcinoma of the lung. Oncogene 1988;3:471-5.
17. Kyoizumi S, Akiyama M, Kouno N, Kobuke K, Hakoda M, Jones SL, et al. Monoclonal antibodies to human squamous cell carcinoma of the lung and their application to tumor diagnosis. Cancer Res 1985;45:3274-81.
18. Solberg HE. Establishment and use of reference values. In: Burtis CA, Ashwood ER, editors. Tietz textbook of clinical chemistry, 3rd ed. Philadelphia: WB Saunders, 1999:336-56.
19. NCCLS. How to define and determine reference intervals in the clinical laboratory; approved guideline, 2nd ed. (NCCLS document C28-A2). Wayne: NCCLS, 2000.
20. Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1999;94:1086-99.
21. Han K, Kahng J, Kim M, Lim J, Kim Y, Cho B, et al. Expression of functional markers in acute nonlymphoblastic leukemia. Acta Haematol 2000;104:174-80.
22. Tafuri A, Gregorj C, Petrucci MT, Ricciardi MR, Mancini M, Cimino G, et al. MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood 2002;100:974-81.
23. Broxterman HJ, Sonneveld P, van Putten WJ, Lankelma J, Eekman CA, Ossenkoppele GJ, et al. P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy. Leukemia 2000;14:1018-24.
24. List AF, Kopecky KJ, Willman CL, Head DR, Persons DL, Slovak ML, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 2001;98:3212-20.